In celebration of National Nurses Week, May 6-12, Boca Raton Regional Hospital hosted a day of appreciation and wellness for its nurses. They were gifted complimentary makeovers, hair styling, nail and eyebrow services, massages, facials and meditation on behalf of the Boca Raton Regional Hospital Foundation and Bloomingdale’s.
***
Heather Havericak and Dr. Jacqueline Tutiven at the Go Red for Women event on cardiovascular health. Photo provided
Event promotes women’s heart health
The American Heart Association’s Go Red for Women event was held in April in Palm Beach Gardens with more than 300 people attending. Go Red for Women aims to raise awareness and funds for women’s cardiovascular health.
“Cardiovascular disease is still the No. 1 killer of women, and events like this one are essential to raising awareness and providing education so women understand their risks — and how to reduce them,” said Heather Havericak, Palm Beach Go Red for Women chair and chief executive officer of Delray Medical Center.
Dr. Jacqueline Tutiven, medical director of Palm Beach Health Network Anesthesiology for Delray Medical Center and West Boca Medical Center, was named Woman of Impact. Valentina Mugica was named Teen of Impact. They were honored for their roles in fundraising, advocacy and championing heart health.
Two new systems for heart treatment
Delray Medical Center now uses the new Abbott’s Volt Pulsed Field Ablation System to treat A-fib, with electrophysiologist Dr. Yoel Vivas performing the first procedure. Pulsed field ablation is different from thermal ablation, which has been the A-fib standard for decades. Pulsed field ablation disables the cardiac tissue causing A-fib, using high-energy electrical pulses rather than extreme temperatures.
Delray Medical Center is also now using the Evoque Tricuspid Valve Replacement System, offering a treatment option for patients with severe tricuspid regurgitation. A historically underdiagnosed and undertreated condition, tricuspid regurgitation can lead to symptoms including fatigue, swelling and heart failure.
Company on fast track to treat Alzheimer’s
The Boca Raton biotechnology company INmune Bio received a Fast Track designation from the U.S. Food and Drug Administration for XPro, a therapeutic agent to treat Alzheimer’s in patients with biomarkers of neuroinflammation.
“We believe XPro has the potential to significantly alter the trajectory of this devastating disease, and we look forward to working more closely with the FDA to bring this therapy to patients as efficiently as possible,” INmune Bio CEO David Moss said.
INmune Bio completed a phase 2 clinical trial for XPro that showed the treatment had cognitive, behavioral and biological benefits for patients with inflammation. An integrated Phase 2b/3 trial will follow. Inflammation in the brain is a major cause of the development and progression of Alzheimer’s, and there are no FDA-approved drugs to treat it.
By blocking a specific protein in the body that causes inflammation, XPro aims to reduce brain swelling and protect the brain from further damage.
— Christine Davis
Comments